4.7 Article

Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study

Journal

EBIOMEDICINE
Volume 78, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ebiom.2022.103953

Keywords

Type 2 diabetes mellitus; Lipid traits; Mendelian Randomization; PCSK9; HMGCR

Funding

  1. Veterans Administration (VA) Cooperative Studies Program (CSP) award [G002]
  2. Wellcome Trust at the MRC/UVRI [220740/Z/20/Z]
  3. LSHTM
  4. British Heart Foundation Centre of Research Excellence at Imperial College [RE/18/4/34215]
  5. National Institute for Health Research Clinical Lectureship at St. George's, University of London [CL-2020-16-001]
  6. Academy of Finland Project [312123]
  7. European Union [848158]
  8. Makerere University Non-Communicable Diseases (MacNCD)
  9. MakNCD Research Training Program: National Institutes of Health (NIH) through the Fogarty International Center (FIC) [1D43TW011401-01]
  10. EC-Innovative Medicines Initiative (BigData@Heart)
  11. Sir Henry Dale Fellowship - Wellcome Trust [204623/Z/16/Z]
  12. Sir Henry Dale Fellowship - Royal Society [204623/Z/16/Z]
  13. UK Research and Innovation (UKRI) Medical Research Council [MC_UU_00002/)]
  14. National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre [BRC-1215-20014]
  15. Wellcome Trust grant [214205/Z/18/Z]
  16. Wellcome Trust [214205/Z/18/Z] Funding Source: Wellcome Trust
  17. Academy of Finland (AKA) [312123] Funding Source: Academy of Finland (AKA)

Ask authors/readers for more resources

This study used Mendelian Randomization to investigate the causal effect of lipid traits on the susceptibility to type 2 diabetes mellitus (T2DM) in individuals of African ancestry. The results showed that increased levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were associated with increased T2DM liability, while increased levels of high-density lipoprotein cholesterol (HDL-C) were associated with reduced T2DM liability. The study also found that inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), a lipid-lowering drug target, was associated with increased T2DM liability.
Background Dyslipidaemia is highly prevalent in individuals with type 2 diabetes mellitus (T2DM). Numerous studies have sought to disentangle the causal relationship between dyslipidaemia and T2DM liability. However, conventional observational studies are vulnerable to confounding. Mendelian Randomization (MR) studies (which address this bias) on lipids and T2DM liability have focused on European ancestry individuals, with none to date having been performed in individuals of African ancestry. We therefore sought to use MR to investigate the causal effect of various lipid traits on T2DM liability in African ancestry individuals. Methods Using univariable and multivariable two-sample MR, we leveraged summary-level data for lipid traits and T2DM liability from the African Partnership for Chronic Disease Research (APCDR) (N =13,612, 36.9% men) and from African ancestry individuals in the Million Veteran Program (Ncases = 23,305 and Ncontrols = 30,140, 87.2% men), respectively. Genetic instruments were thus selected from the APCDR after which they were clumped to obtain independent instruments. We used a random-effects inverse variance weighted method in our primary analysis, complementing this with additional sensitivity analyses robust to the presence of pleiotropy. Findings Increased genetically proxied low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels were associated with increased T2DM liability in African ancestry individuals (odds ratio (OR) [95% confidence inter-val, P-value] per standard deviation (SD) increase in LDL-C = 1.052 [1.000 to 1.106, P = 0.046] and per SD increase in TC =1.089 [1.014 to 1.170, P = 0.019]). Conversely, increased genetically proxied high-density lipoprotein cholesterol (HDL-C) was associated with reduced T2DM liability (OR per SD increase in HDL-C = 0.915 [0.843 to 0.993, P = 0.033]). The OR on T2DM per SD increase in genetically proxied triglyceride (TG) levels was 0.884 [0.773 to 1.011, P = 0.072] . With respect to lipid-lowering drug targets, we found that genetically proxied 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) inhibition was associated with increased T2DM liability (OR per SD decrease in genetically proxied LDL-C = 1.68 [1.03-2.72, P = 0.04]) but we did not find evidence of a relationship between geneti-cally proxied proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and T2DM liability. Interpretation Consistent with MR findings in Europeans, HDL-C exerts a protective effect on T2DM liability and HMGCR inhibition increases T2DM liability in African ancestry individuals. However, in contrast to European ancestry individuals, LDL-C may increase T2DM liability in African ancestry individuals. This raises the possibility of ethnic differences in the metabolic effects of dyslipidaemia in T2DM. Copyright (c) 2022 The Author(s). Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available